BioNTech SE (BNTX)vsMerck & Company Inc (MRK)
BNTX
BioNTech SE
$101.57
-0.48%
HEALTHCARE · Cap: $25.69B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2165% more annual revenue ($65.01B vs $2.87B). MRK leads profitability with a 28.1% profit margin vs -39.6%. BNTX appears more attractively valued with a PEG of 0.05. MRK earns a higher WallStSmart Score of 59/100 (C).
BNTX
Avoid32
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+37.4%
Fair Value
$174.59
Current Price
$101.57
$73.02 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Weak financial health signals
ROE of -5.9% — below average capital efficiency
Revenue declined 23.7%
Earnings declined 43.2%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BNTX
The strongest argument for BNTX centers on PEG Ratio, Price/Book, Altman Z-Score. PEG of 0.05 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : BNTX
The primary concerns for BNTX are Piotroski F-Score, Return on Equity, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
BNTX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
BNTX carries more volatility with a beta of 1.59 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 32/100), backed by strong 28.1% margins. BNTX offers better value entry with a 37.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioNTech SE
HEALTHCARE · BIOTECHNOLOGY · USA
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?